Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Enfortumab Vedotin Showcases Impressive Safety, Efficacy in Cisplatin-Ineligible Urothelial Cancer
February 13th 2021February 12, 2021 - Enfortumab vedotin elicited the highest response rates observed for any regimen examined in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors.
Dr. Bergerot on Improved HRQoL With a Higher Starting Dose of Lenvatinib Plus Everolimus in RCC
February 13th 2021Cristiane Bergerot PhD, MS, BS, discusses how a higher starting dose of lenvatinib, to be combined with everolimus, can improve health-related quality of life in patients with renal cell carcinoma, as demonstrated in a phase 2 open-label trial.
Frontline Nivolumab/Cabozantinib Maintains Survival Benefit Over Sunitinib in Advanced RCC
February 12, 2021 - The combination of nivolumab and cabozantinib continued to showcase a superior survival benefit over single-agent sunitinib when used as first-line treatment in patients with advanced renal cell carcinoma.
Dr. Efstathiou on the rPFS Benefit Achieved With Apalutamide Regimen in mCRPC
February 12th 2021Eleni Efstathiou, MD, discusses the key findings of the placebo-controlled, double-blind phase 3 ACIS study of apalutamide and abiraterone acetate plus prednisone versus prednisone alone in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer.
Crossover Minimally Impacts OS Benefit Achieved With Darolutamide in ARAMIS Trial
February 12th 2021February 12, 2021 - Crossover from placebo to darolutamide appeared to have minimal impact on the overall survival benefit experienced by patients with nonmetastatic castration-resistant prostate cancer who were enrolled to the pivotal phase 3 ARAMIS trial.
Atezolizumab Demonstrates Clinical Activity in PD-L1–High Metastatic Urothelial Carcinoma
February 12th 2021February 12, 2021 - Atezolizumab monotherapy showed favorable outcomes compared with chemotherapy alone as frontline treatment for patients with cisplatin-ineligible IC2/3 advanced or metastatic urothelial carcinoma.
PSMA-Targeted Agent Shows Potential Utility in Identifying Relapsed Prostate Cancer
February 12th 2021February 12, 2021 - The novel prostate specific membrane antigen–targeted radiopharmaceutical for PET imaging technique, 18F-DCFPyL, demonstrated potential in identifying occult prostate cancer and more accurately characterizing disease burden.
Prolonged Treatment With Darolutamide Is Well Tolerated in Nonmetastic CRPC
February 12th 2021February 12, 2021 - The androgen receptor inhibitor darolutamide continues to show favorable tolerability in patients with nonmetastatic castration-resistant prostate cancer, even when given for a prolonged period of time.
Apalutamide Plus Abiraterone Reduces Risk of Progression in mCRPC
February 11th 2021February 11, 2021 - Adding apalutamide to abiraterone acetate and prednisone reduced the risk of radiographic progression or death by 30% in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer receiving androgen deprivation therapy.
Orca-T Displays GVHD Prevention, Scalability Potential, and Tolerability in Hematologic Cancers
February 11, 2021 - Treatment with the first-generation precision cell therapy Orca-T led to a significant reduction in cases of graft-versus-host disease, an impressive GVHD relapse-free survival rate, a lack of treatment-related mortalities, while showcasing scalability potential.
VERU-111 Elicits Early Efficacy Signals in Pretreated mCRPC
February 11th 2021February 11, 2021 - The novel tubulin inhibitor VERU-111 demonstrated early antitumor activity and a well-tolerated safety profile in patients with metastatic castration-resistant prostate cancer who failed a prior androgen receptor–targeting agent.
Frontline Immunotherapy Correlates With Improved OS Over TKIs in Advanced Non–Clear Cell RCC
February 11, 2021 - First-line treatment with immune checkpoint inhibitor–based regimens could be linked with an improvement in overall survival versus select targeted therapies in patients with metastatic non–clear cell renal cell carcinoma.
Higher Lenvatinib Dose May Improve QoL in RCC
February 11th 2021February 11, 2021 - A higher starting dose of lenvatinib — 18 mg per day — improved health-related quality of life and led to longer time to deterioration compared with a lower starting dose of lenvatinib — 14 mg per day — in patients with renal cell carcinoma.
Lenvatinib Plus Everolimus Safe, Effective Following Immunotherapy in Clear Cell RCC
February 11th 2021February 11, 2021 - Lenvatinib in combination with everolimus has proven to be safe and effective when used in the treatment of patients with clear cell renal cell carcinoma who had previously received an immune checkpoint inhibitor.
Iomab-B/Transplant Causes Fewer AEs Versus Conventional Care in AML
February 11th 2021February 11, 2021 - A conditioning regimen comprised of targeted radiation with Iomab-B led to a lower incidence of sepsis as well as trends toward reduced rates of severe mucositis and febrile neutropenia versus conventional care and standard conditioning regimens in older adults with relapsed or refractory acute myeloid leukemia.
Apamistamab Conditioning Treatment Induces High Rates of HCT Success in AML
February 11, 2021 — Apamistamab conditioning treatment with targeted radioimmunotherapy to the bone marrow resulted in high rates of successful allogeneic hematopoietic stem cell transplants in patients with active, relapsed, or refractory acute myeloid leukemia.
Dr. Choudhury on the Rationale Behind Adding Pembrolizumab to Radium-223 in mCRPC
February 11th 2021Atish D. Choudhury, MD, PhD, discusses the rationale behind combining pembrolizumab with radium-223 in patients with metastatic castration-resistant prostate cancer as part of a phase 2 clinical trial.
